https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Immunotherapy 2014;6(3):349-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Immunotherapy 2014;6(3):349-602014-01-01 00:00:002019-02-15 08:50:00Dendritic cell-based vaccines: clinical applications in breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Methods Mol. Biol. 2014;1139:33-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Methods Mol. Biol. 2014;1139:33-402014-01-01 00:00:002019-02-15 08:39:43Antigen trapping by dendritic cells for antitumor therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Hum Vaccin Immunother 2014;10(11):3125-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Hum Vaccin Immunother 2014;10(11):3125-312014-01-01 00:00:002019-02-15 08:32:45Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Methods Mol. Biol. 2014;1139:17-26
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Methods Mol. Biol. 2014;1139:17-262014-01-01 00:00:002019-02-15 08:39:43Generation of multiple peptide cocktail-pulsed dendritic cells as a cancer vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Immunotherapy 2014;6(11):1221-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Immunotherapy 2014;6(11):1221-352014-01-01 00:00:002019-02-15 08:45:40Immunotherapy and lung cancer: current developments and novel targeted therapies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Hum Vaccin Immunother 2014;10(7):1822-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Hum Vaccin Immunother 2014;10(7):1822-72014-01-01 00:00:002024-03-18 11:00:32Dendritic cell immunotherapy in uterine cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Hum Vaccin Immunother 2014;10(11):3261-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Hum Vaccin Immunother 2014;10(11):3261-92014-01-01 00:00:002019-02-15 08:39:33Tumor cell lysates as immunogenic sources for cancer vaccine design
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Hum Vaccin Immunother 2014;10(11):3132-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Hum Vaccin Immunother 2014;10(11):3132-82014-01-01 00:00:002021-12-15 16:11:43Novel dendritic cell-based vaccination in late stage melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Expert Rev Vaccines 2014 Jan;13(1):117-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Expert Rev Vaccines 2014 Jan;13(1):117-302014-01-01 00:00:002021-11-15 16:55:45Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-12-13 / Front Immunol 2013 Dec;4:454
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-12-13 / Front Immunol 2013 Dec;4:4542013-12-13 00:00:002019-02-15 08:39:46Dendritic cells in cancer immunotherapy clinical trials: are we making progress?
